Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis
Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases. To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis. We studied prospectively 100 stabl...
Gespeichert in:
| Veröffentlicht in: | Digestive and liver disease 2019-12, Vol.51 (12), p.1692-1697 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1697 |
|---|---|
| container_issue | 12 |
| container_start_page | 1692 |
| container_title | Digestive and liver disease |
| container_volume | 51 |
| creator | Oikonomou, Theodora Goulis, Ioannis Ntogramatzi, Fani Athanasiadou, Zoi Vagdatli, Eleni Akriviadis, Evangelos Cholongitas, Evangelos |
| description | Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases.
To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis.
We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients’ renal function was assessed using 51Chromium-EDTA (“true GFR”).
Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had ≥11.7 ng/mL; they differed significantly regarding mean “true”-GFR: 90 ± 20 mL/min vs. 76 ± 26 mL/min, p = 0.03 and mean creatinine: 0.83 ± 0.14 mg/dL vs. 0.97 ± 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9–76.5 ng/mL); 49 patients with gal-3 ≥17.5 ng/mL had significantly higher MELD score, (15 ± 5 vs. 13 ± 4, p = 0.02) and worse “true” GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting “true”-GFR |
| doi_str_mv | 10.1016/j.dld.2019.05.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2246906478</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1590865819306310</els_id><sourcerecordid>2246906478</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-df294a1aff3dcdb4470eff26eb864dee0cfa28bff439307dc24d6d5b81838d8f3</originalsourceid><addsrcrecordid>eNp9kD1PHDEQhi0UBITkB9Agl2l2449dn1dUCCUkElKaUFteeww--daHx5uIf4_JkZSpxtI87yvPQ8gFZz1nXH3e9j75XjA-9WzsmWRH5Izrje7kqMS79h4n1mk16lPyHnHLmOBqZCfkVHIhR8nlGam3NoGrcekkjUgtYnbRVvD0d6yP9CHlHZQ12UJDTLXYGvNC2wBqF0_zWl0DaFzovq1gqXjIYbVzAuqhrfew4J9GF0t5zBjxAzkONiF8fJvn5P7rl58337q7H7ffb67vOtd-VzsfxDRYbkOQ3vl5GDYMQhAKZq0GD8BcsELPIQxykmzjnRi88uOsuZba6yDPyadD777kpxWwml1EBynZBfKKRohBTUwNG91QfkBdyYgFgtmXuLPl2XBmXmWbrWmyzatsw0bTZLfM5Vv9Ou_A_0v8tduAqwMA7chfEYpB1yQ58LE06cbn-J_6F1VdksM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246906478</pqid></control><display><type>article</type><title>Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Oikonomou, Theodora ; Goulis, Ioannis ; Ntogramatzi, Fani ; Athanasiadou, Zoi ; Vagdatli, Eleni ; Akriviadis, Evangelos ; Cholongitas, Evangelos</creator><creatorcontrib>Oikonomou, Theodora ; Goulis, Ioannis ; Ntogramatzi, Fani ; Athanasiadou, Zoi ; Vagdatli, Eleni ; Akriviadis, Evangelos ; Cholongitas, Evangelos</creatorcontrib><description>Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases.
To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis.
We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients’ renal function was assessed using 51Chromium-EDTA (“true GFR”).
Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had ≥11.7 ng/mL; they differed significantly regarding mean “true”-GFR: 90 ± 20 mL/min vs. 76 ± 26 mL/min, p = 0.03 and mean creatinine: 0.83 ± 0.14 mg/dL vs. 0.97 ± 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9–76.5 ng/mL); 49 patients with gal-3 ≥17.5 ng/mL had significantly higher MELD score, (15 ± 5 vs. 13 ± 4, p = 0.02) and worse “true” GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting “true”-GFR < 60 mL/min; AUC: 0.71, 95%CI [0.58–0.85], best cut off value 17.5 ng/mL. Kaplan–Meier analysis, using median gal-3 (17.5 ng/mL) revealed different survival time for our patients (log-rank p = 0.04).
Gal-3 proved trustworthy marker of established chronic kidney disease, with predictive ability in stable decompensated cirrhosis. Gal-3 came also a significant factor for our patients’ outcome.</description><identifier>ISSN: 1590-8658</identifier><identifier>EISSN: 1878-3562</identifier><identifier>DOI: 10.1016/j.dld.2019.05.030</identifier><identifier>PMID: 31235313</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Cirrhosis ; Clinical Deterioration ; Correlation of Data ; Decompensated cirrhosis ; Female ; Galectin 3 - blood ; Galectin-3 ; Glomerular Filtration Rate ; Greece ; Humans ; Kaplan-Meier Estimate ; Kidney ; Liver ; Liver Cirrhosis - blood ; Liver Cirrhosis - complications ; Liver Cirrhosis - mortality ; Liver Cirrhosis - physiopathology ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Renal function ; Renal Insufficiency, Chronic - blood ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - epidemiology ; Renal Insufficiency, Chronic - physiopathology</subject><ispartof>Digestive and liver disease, 2019-12, Vol.51 (12), p.1692-1697</ispartof><rights>2019 Editrice Gastroenterologica Italiana S.r.l.</rights><rights>Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-df294a1aff3dcdb4470eff26eb864dee0cfa28bff439307dc24d6d5b81838d8f3</citedby><cites>FETCH-LOGICAL-c353t-df294a1aff3dcdb4470eff26eb864dee0cfa28bff439307dc24d6d5b81838d8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.dld.2019.05.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31235313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oikonomou, Theodora</creatorcontrib><creatorcontrib>Goulis, Ioannis</creatorcontrib><creatorcontrib>Ntogramatzi, Fani</creatorcontrib><creatorcontrib>Athanasiadou, Zoi</creatorcontrib><creatorcontrib>Vagdatli, Eleni</creatorcontrib><creatorcontrib>Akriviadis, Evangelos</creatorcontrib><creatorcontrib>Cholongitas, Evangelos</creatorcontrib><title>Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases.
To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis.
We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients’ renal function was assessed using 51Chromium-EDTA (“true GFR”).
Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had ≥11.7 ng/mL; they differed significantly regarding mean “true”-GFR: 90 ± 20 mL/min vs. 76 ± 26 mL/min, p = 0.03 and mean creatinine: 0.83 ± 0.14 mg/dL vs. 0.97 ± 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9–76.5 ng/mL); 49 patients with gal-3 ≥17.5 ng/mL had significantly higher MELD score, (15 ± 5 vs. 13 ± 4, p = 0.02) and worse “true” GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting “true”-GFR < 60 mL/min; AUC: 0.71, 95%CI [0.58–0.85], best cut off value 17.5 ng/mL. Kaplan–Meier analysis, using median gal-3 (17.5 ng/mL) revealed different survival time for our patients (log-rank p = 0.04).
Gal-3 proved trustworthy marker of established chronic kidney disease, with predictive ability in stable decompensated cirrhosis. Gal-3 came also a significant factor for our patients’ outcome.</description><subject>Cirrhosis</subject><subject>Clinical Deterioration</subject><subject>Correlation of Data</subject><subject>Decompensated cirrhosis</subject><subject>Female</subject><subject>Galectin 3 - blood</subject><subject>Galectin-3</subject><subject>Glomerular Filtration Rate</subject><subject>Greece</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney</subject><subject>Liver</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Renal function</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - epidemiology</subject><subject>Renal Insufficiency, Chronic - physiopathology</subject><issn>1590-8658</issn><issn>1878-3562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PHDEQhi0UBITkB9Agl2l2449dn1dUCCUkElKaUFteeww--daHx5uIf4_JkZSpxtI87yvPQ8gFZz1nXH3e9j75XjA-9WzsmWRH5Izrje7kqMS79h4n1mk16lPyHnHLmOBqZCfkVHIhR8nlGam3NoGrcekkjUgtYnbRVvD0d6yP9CHlHZQ12UJDTLXYGvNC2wBqF0_zWl0DaFzovq1gqXjIYbVzAuqhrfew4J9GF0t5zBjxAzkONiF8fJvn5P7rl58337q7H7ffb67vOtd-VzsfxDRYbkOQ3vl5GDYMQhAKZq0GD8BcsELPIQxykmzjnRi88uOsuZba6yDPyadD777kpxWwml1EBynZBfKKRohBTUwNG91QfkBdyYgFgtmXuLPl2XBmXmWbrWmyzatsw0bTZLfM5Vv9Ou_A_0v8tduAqwMA7chfEYpB1yQ58LE06cbn-J_6F1VdksM</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Oikonomou, Theodora</creator><creator>Goulis, Ioannis</creator><creator>Ntogramatzi, Fani</creator><creator>Athanasiadou, Zoi</creator><creator>Vagdatli, Eleni</creator><creator>Akriviadis, Evangelos</creator><creator>Cholongitas, Evangelos</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201912</creationdate><title>Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis</title><author>Oikonomou, Theodora ; Goulis, Ioannis ; Ntogramatzi, Fani ; Athanasiadou, Zoi ; Vagdatli, Eleni ; Akriviadis, Evangelos ; Cholongitas, Evangelos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-df294a1aff3dcdb4470eff26eb864dee0cfa28bff439307dc24d6d5b81838d8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cirrhosis</topic><topic>Clinical Deterioration</topic><topic>Correlation of Data</topic><topic>Decompensated cirrhosis</topic><topic>Female</topic><topic>Galectin 3 - blood</topic><topic>Galectin-3</topic><topic>Glomerular Filtration Rate</topic><topic>Greece</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney</topic><topic>Liver</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Renal function</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - epidemiology</topic><topic>Renal Insufficiency, Chronic - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oikonomou, Theodora</creatorcontrib><creatorcontrib>Goulis, Ioannis</creatorcontrib><creatorcontrib>Ntogramatzi, Fani</creatorcontrib><creatorcontrib>Athanasiadou, Zoi</creatorcontrib><creatorcontrib>Vagdatli, Eleni</creatorcontrib><creatorcontrib>Akriviadis, Evangelos</creatorcontrib><creatorcontrib>Cholongitas, Evangelos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oikonomou, Theodora</au><au>Goulis, Ioannis</au><au>Ntogramatzi, Fani</au><au>Athanasiadou, Zoi</au><au>Vagdatli, Eleni</au><au>Akriviadis, Evangelos</au><au>Cholongitas, Evangelos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2019-12</date><risdate>2019</risdate><volume>51</volume><issue>12</issue><spage>1692</spage><epage>1697</epage><pages>1692-1697</pages><issn>1590-8658</issn><eissn>1878-3562</eissn><abstract>Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases.
To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis.
We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients’ renal function was assessed using 51Chromium-EDTA (“true GFR”).
Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had ≥11.7 ng/mL; they differed significantly regarding mean “true”-GFR: 90 ± 20 mL/min vs. 76 ± 26 mL/min, p = 0.03 and mean creatinine: 0.83 ± 0.14 mg/dL vs. 0.97 ± 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9–76.5 ng/mL); 49 patients with gal-3 ≥17.5 ng/mL had significantly higher MELD score, (15 ± 5 vs. 13 ± 4, p = 0.02) and worse “true” GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting “true”-GFR < 60 mL/min; AUC: 0.71, 95%CI [0.58–0.85], best cut off value 17.5 ng/mL. Kaplan–Meier analysis, using median gal-3 (17.5 ng/mL) revealed different survival time for our patients (log-rank p = 0.04).
Gal-3 proved trustworthy marker of established chronic kidney disease, with predictive ability in stable decompensated cirrhosis. Gal-3 came also a significant factor for our patients’ outcome.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31235313</pmid><doi>10.1016/j.dld.2019.05.030</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2019-12, Vol.51 (12), p.1692-1697 |
| issn | 1590-8658 1878-3562 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2246906478 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Cirrhosis Clinical Deterioration Correlation of Data Decompensated cirrhosis Female Galectin 3 - blood Galectin-3 Glomerular Filtration Rate Greece Humans Kaplan-Meier Estimate Kidney Liver Liver Cirrhosis - blood Liver Cirrhosis - complications Liver Cirrhosis - mortality Liver Cirrhosis - physiopathology Male Middle Aged Predictive Value of Tests Prognosis Renal function Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - physiopathology |
| title | Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T03%3A51%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Galectin-3%20is%20associated%20with%20glomerular%20filtration%20rate%20and%20outcome%20in%20patients%20with%20stable%20decompensated%20cirrhosis&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Oikonomou,%20Theodora&rft.date=2019-12&rft.volume=51&rft.issue=12&rft.spage=1692&rft.epage=1697&rft.pages=1692-1697&rft.issn=1590-8658&rft.eissn=1878-3562&rft_id=info:doi/10.1016/j.dld.2019.05.030&rft_dat=%3Cproquest_cross%3E2246906478%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246906478&rft_id=info:pmid/31235313&rft_els_id=S1590865819306310&rfr_iscdi=true |